Black Diamond Therapeutics, Inc.
BDTX
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$43M
▲ +132.1% YoY
Op. Margin
17.89%
ROIC
-32.03%
▲ +58.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$33M
▲ +147.5% YoY
Op. Cash Flow (TTM)
-$33M
▲ +147.5% YoY
Net Debt
-$94M
Net Cash Position
Cash & Equiv.
$111M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BDTX
Held by ETFs
BDTX is in 11 US ETFs. The largest of them, with BDTX's weight in each:
Avantis U.S. Small Cap Value ETFAVUV0.00%of the fund
iShares Biotechnology ETFIBB0.01%of the fund
Dimensional US Small Cap Value ETFDFSV0.00%of the fund
Fidelity Enhanced Small Cap ETFFESM0.02%of the fund
iShares U.S. Small-Cap Equity Factor ETFSMLF0.02%of the fund
- BSEA Bridgeway Omni Small-Cap Value ETFBSVO0.02%of the fund
Black Diamond Therapeutics (BDTX) in three numbers
Questions about Black Diamond Therapeutics
Is Black Diamond Therapeutics a high-quality business?
Black Diamond Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$94M, and its weakest is return on capital at -32.0%. The Quality tab shows every check against its target.
Does Black Diamond Therapeutics (BDTX) pay a dividend?
No. Black Diamond Therapeutics (BDTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BDTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BDTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.